Rolipram attenuates MK-801-induced deficits in latent inhibition

Jennifer A. Davis, Thomas J. Gould

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Latent inhibition is used to examine attention and study cognitive deficits associated with schizophrenia. Research using MK-801, an N-methyl-D-aspartate (NMDA) open channel blocker, implicates glutamate receptors in acquisition of latent inhibition of cued fear conditioning. Evidence suggests an important relationship between NMDA-induced increases in cyclic adenosine monophosphate (cAMP) and learning and memory. The authors examine whether amplification of the cAMP signaling pathway by rolipram, a selective Type 4 cAMP phosphodiesterase inhibitor, reverses MK-801-induced impairments in latent inhibition. One day before training, mice were injected with MK-801, rolipram, MK-801 and rolipram, or vehicle and received 20 preexposures or no preexposures to an auditory conditioned stimulus (CS). Training consisted of 2 CS-footshock unconditioned stimulus pairings. Rolipram attenuated the disruptive effect of MK-801 on latent inhibition, which suggests a role for the cAMP signaling pathway in the task and implicates phosphodiesterase inhibition as a target for treating cognitive impairments associated with schizophrenia.

Original languageEnglish (US)
Pages (from-to)595-602
Number of pages8
JournalBehavioral Neuroscience
Volume119
Issue number2
DOIs
StatePublished - Apr 1 2005

Fingerprint

Rolipram
Dizocilpine Maleate
Cyclic AMP
N-Methylaspartate
Schizophrenia
Phosphodiesterase Inhibitors
Phosphoric Diester Hydrolases
Glutamate Receptors
Fear
Inhibition (Psychology)
Learning
Research

All Science Journal Classification (ASJC) codes

  • Behavioral Neuroscience

Cite this

@article{c955a1b9af2343929b00794aab03edcc,
title = "Rolipram attenuates MK-801-induced deficits in latent inhibition",
abstract = "Latent inhibition is used to examine attention and study cognitive deficits associated with schizophrenia. Research using MK-801, an N-methyl-D-aspartate (NMDA) open channel blocker, implicates glutamate receptors in acquisition of latent inhibition of cued fear conditioning. Evidence suggests an important relationship between NMDA-induced increases in cyclic adenosine monophosphate (cAMP) and learning and memory. The authors examine whether amplification of the cAMP signaling pathway by rolipram, a selective Type 4 cAMP phosphodiesterase inhibitor, reverses MK-801-induced impairments in latent inhibition. One day before training, mice were injected with MK-801, rolipram, MK-801 and rolipram, or vehicle and received 20 preexposures or no preexposures to an auditory conditioned stimulus (CS). Training consisted of 2 CS-footshock unconditioned stimulus pairings. Rolipram attenuated the disruptive effect of MK-801 on latent inhibition, which suggests a role for the cAMP signaling pathway in the task and implicates phosphodiesterase inhibition as a target for treating cognitive impairments associated with schizophrenia.",
author = "Davis, {Jennifer A.} and Gould, {Thomas J.}",
year = "2005",
month = "4",
day = "1",
doi = "10.1037/0735-7044.119.2.595",
language = "English (US)",
volume = "119",
pages = "595--602",
journal = "Behavioral Neuroscience",
issn = "0735-7044",
publisher = "American Psychological Association Inc.",
number = "2",

}

Rolipram attenuates MK-801-induced deficits in latent inhibition. / Davis, Jennifer A.; Gould, Thomas J.

In: Behavioral Neuroscience, Vol. 119, No. 2, 01.04.2005, p. 595-602.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Rolipram attenuates MK-801-induced deficits in latent inhibition

AU - Davis, Jennifer A.

AU - Gould, Thomas J.

PY - 2005/4/1

Y1 - 2005/4/1

N2 - Latent inhibition is used to examine attention and study cognitive deficits associated with schizophrenia. Research using MK-801, an N-methyl-D-aspartate (NMDA) open channel blocker, implicates glutamate receptors in acquisition of latent inhibition of cued fear conditioning. Evidence suggests an important relationship between NMDA-induced increases in cyclic adenosine monophosphate (cAMP) and learning and memory. The authors examine whether amplification of the cAMP signaling pathway by rolipram, a selective Type 4 cAMP phosphodiesterase inhibitor, reverses MK-801-induced impairments in latent inhibition. One day before training, mice were injected with MK-801, rolipram, MK-801 and rolipram, or vehicle and received 20 preexposures or no preexposures to an auditory conditioned stimulus (CS). Training consisted of 2 CS-footshock unconditioned stimulus pairings. Rolipram attenuated the disruptive effect of MK-801 on latent inhibition, which suggests a role for the cAMP signaling pathway in the task and implicates phosphodiesterase inhibition as a target for treating cognitive impairments associated with schizophrenia.

AB - Latent inhibition is used to examine attention and study cognitive deficits associated with schizophrenia. Research using MK-801, an N-methyl-D-aspartate (NMDA) open channel blocker, implicates glutamate receptors in acquisition of latent inhibition of cued fear conditioning. Evidence suggests an important relationship between NMDA-induced increases in cyclic adenosine monophosphate (cAMP) and learning and memory. The authors examine whether amplification of the cAMP signaling pathway by rolipram, a selective Type 4 cAMP phosphodiesterase inhibitor, reverses MK-801-induced impairments in latent inhibition. One day before training, mice were injected with MK-801, rolipram, MK-801 and rolipram, or vehicle and received 20 preexposures or no preexposures to an auditory conditioned stimulus (CS). Training consisted of 2 CS-footshock unconditioned stimulus pairings. Rolipram attenuated the disruptive effect of MK-801 on latent inhibition, which suggests a role for the cAMP signaling pathway in the task and implicates phosphodiesterase inhibition as a target for treating cognitive impairments associated with schizophrenia.

UR - http://www.scopus.com/inward/record.url?scp=17444381935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17444381935&partnerID=8YFLogxK

U2 - 10.1037/0735-7044.119.2.595

DO - 10.1037/0735-7044.119.2.595

M3 - Article

C2 - 15839805

AN - SCOPUS:17444381935

VL - 119

SP - 595

EP - 602

JO - Behavioral Neuroscience

JF - Behavioral Neuroscience

SN - 0735-7044

IS - 2

ER -